ACS receives grant to develop next generation of alcohol sensing technology

Alcohol Countermeasure Systems Corp (ACS) has been awarded a $3.15 million grant from the Ontario Ministry of Economic Development and Trade for the development of next generation alcohol sensing technology over the next four years. This grant augments an $18 million commitment from ACS to develop and commercialize the next generation of alcohol sensing technology.

These sensors are the key component to alcohol interlocks - the breath alcohol testers that require drivers to provide a breath sample prior to starting their vehicle. Alcohol interlocks are commonly used in compliance monitoring for convicted impaired drivers or for commercial fleets as a pro-active safety measure.

The grant, combined with the ACS portion will mean 105 new jobs at the company over the next four years as well as related research projects facilitated at local universities.

Quotes:

"Investments in new technology and products are essential to remaining competitive. The support from the Government of Ontario helps us add to our team of skilled workers, attract new business and stay ahead of our competitors."

- Felix Comeau, Chairman & CEO of Alcohol Countermeasure Systems Corp.

"ACS is an innovative Ontario company that is succeeding in global markets. Today's investment not only creates jobs, but also generates spin-off economic activity and learning opportunities in a specialized field. Ontario's highly skilled workforce and competitive business environment are key factors in attracting investment from innovative and growing companies like ACS."

- Sandra Pupatello, Minister of Economic Development and Trade

Source:

ALCOHOL COUNTERMEASURE SYSTEMS CORP.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Oral medication sodium oxybate shows promise for treating laryngeal dystonia